Insmed Incorporated Reports Financial Results for the First Quarter Ended March 31, 2006
08 Mai 2006 - 10:05PM
Business Wire
Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company
focused on the development and commercialization of drugs for the
treatment of metabolic and endocrine diseases with unmet medical
needs, today announced results for the three month period ended
March 31, 2006. -0- *T $000's (except EPS) Q1 2006 Q1 2005
------------------------------ Revenues 54 57 Net loss (13,427)
(5,764) Net cash used in operations 11,678 6,295 Earnings per share
(0.17) (0.13)
--------------------------------------------------------- *T
Discussion of Revenue and Expense Items Revenues for the three
months ended March 31, 2006 were $54,000 as compared to $57,000 for
the corresponding period of 2005. The net loss for the first
quarter ended March 31, 2006 was $13.4 million or $0.17 per share,
as compared to a net loss of $5.8 million or $0.13 per share for
the corresponding quarter of 2005. The $7.7 million increase in the
net loss for the first quarter of 2006, as compared to the
corresponding quarter of 2005, was due to increases of $2.9 million
in research and development (R&D), $2.5 in selling, general and
administration (SG&A) and $2.5 million in interest expense.
These increases in expense were partially offset by a $0.2 million
rise in interest income. The increases in R&D and SG&A
expenses resulted primarily from higher production and marketing
expenses in support of our planned Q2 2006 IPLEX(TM) product
launch, which remains on track, plus additional expenses related to
the ongoing patent infringement and unfair business practices
litigation. The increase in interest expense, all of which is
non-cash, is due entirely to the acceleration of the debt discount
on the March 2005 convertible notes, a number of which were
converted during the first quarter of 2006. The increased
investment income results mainly from the higher cash balance
available for investment in the first quarter of 2006 as compared
to the corresponding period of 2005. As of March 31, 2006, the
company had total cash and cash equivalents of $59.2 million which
represents an increase of $40.4 million from December 31, 2005.
This increase is mainly due to the $52.1 million in net cash
provided by financing activities during the quarter, which includes
the recent sale of equity and the cash from recent warrant
exercises, and was partially offset by the use of $11.7 million in
support of our business operations. Conference Call Insmed will
host a conference call on Monday, May 8, at 4:30 p.m. Eastern Time
to discuss the financial results for the first quarter of 2006 and
provide a business update. Interested investors can listen to the
call over the internet from Insmed's investor relations website at
www.insmed.com or by dialing (800) 475 -3716 (domestic) or (719)
457-2728 (international), passcode: 9480743 A telephonic replay of
the call will be available for one week at (888) 203 -1112
(domestic) or (719) 457-0820 (international), passcode: 9480743. A
web replay of the call will be available through our corporate
website, in the investor relations segment, beginning at 6:00 p.m.
Eastern Time. About Insmed Incorporated Insmed is a
biopharmaceutical company focused on the development and
commercialization of drug candidates for the treatment of metabolic
diseases and endocrine disorders with unmet medical needs. For more
information, please visit www.insmed.com. The company's leading
product, IPLEX was approved as an orphan drug by the United States
Food and Drug Administration in December 2005 for the treatment of
growth failure in children with severe primary IGF-I deficiency
(Primary IGFD) or with growth hormone (GH) gene deletion who have
developed neutralizing antibodies to GH. About IPLEX IPLEX, a
complex of recombinant human IGF-I and its binding protein IGFBP-3
(rhIGF-I/rhIGFBP-3), is the only once-daily IGF-I replacement
therapy. It is also the only FDA-approved therapy that provides
both IGF-I and IGFBP-3 to treat children with severe primary IGFD.
The drug, to be launched during the second quarter of 2006, is also
being investigated for the treatment of various other diseases with
unmet medical needs, including extreme insulin resistance, myotonic
muscular dystrophy and HIV Associated Adipose Redistribution
Syndrome (HARS). About the Condition Severe primary IGFD is a
genetic or acquired condition in which patients do not generate
sufficient quantities of insulin-like growth factor-I (IGF-I) due
to defect in the growth hormone (GH) receptor/IGF-I pathway. Gene
mutations leading to growth failure due to IGF-I deficiency have
been identified in the growth hormone receptor, in the GH receptor
signalling pathway, and in the IGF-I gene itself. Patients with
severe primary IGFD present with marked short stature and a poor
prognosis for adult stature. Statements included within this press
release, which are not historical in nature, may constitute
forward-looking statements for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are
not limited to, statements regarding planned clinical trial design,
our regulatory and business strategies, plans and objectives of
management and growth opportunities for existing or proposed
products. Such forward-looking statements are subject to numerous
risks and uncertainties, including risks that product candidates
may fail in the clinic or may not be successfully marketed or
manufactured, we may lack financial resources to complete
development of product candidates, the FDA may interpret the
results of our studies differently than we have, competing products
may be more successful, demand for new pharmaceutical products may
decrease, the biopharmaceutical industry may experience negative
market trends and other risks detailed from time to time in our
filings with the Securities and Exchange Commission. As a result of
these and other risks and uncertainties, actual results may differ
materially from those described in this press release. For further
information with respect to factors that could cause actual results
to differ from expectations, reference is made to our reports filed
by the Company with the Securities and Exchange Commission under
the Securities Exchange Act of 1934, as amended. The
forward-looking statements made in this release are made only as of
the date hereof and Insmed disclaims any intention or
responsibility for updating predictions or financial guidance
contained in this release. -0- *T INSMED INCORPORATED Condensed
Consolidated Balance Sheets (in thousands, except share and per
share data) March 31, Dec. 31, 2006 2005 ---------- ---------
Assets Current assets: Cash and cash equivalents $59,207 $18,835
Restricted cash 285 285 Other current assets 33 83 ----------
--------- Total current assets 59,525 19,203 Long-term assets:
Restricted cash - long term 2,830 3,118 Deferred financing costs,
net 270 532 Property and equipment, net 15 17 ---------- ---------
Total long-term assets 3,115 3,667 Total assets $62,640 $22,870
========== ========= Liabilities and stockholders' equity Current
liabilities: Accounts payable $ 2,243 $ 968 Accrued project costs
& other 4 1,990 Payroll liabilities 926 1,574 Interest payable
28 52 Restructuring reserve 204 286 ---------- --------- Total
current liabilities 3,405 4,870 Long-term liabilities: Convertible
debt 6,013 11,438 Debt discount (2,539) (5,001) ----------
--------- Net convertible debt 3,474 6,437 Asset retirement
obligation 1,182 1,034 ------------------------- Total liabilities
8,061 12,341 ---------- --------- Stockholders' equity: Common
stock; $.01 par value; authorized share 500,000,000; issued and
outstanding shares, 100,150,700 in 2006 and 66,525,792 in 2005
1,001 665 Additional paid-in capital 321,663 264,522 Accumulated
deficit (268,085) (254,658) ---------- --------- Net stockholders'
equity 54,579 10,529 ---------- --------- Total liabilities and
stockholders' equity $62,640 $22,870 ========== ========= INSMED
INCORPORATED Condensed Consolidated Statements of Operations (in
thousands, except per share data - unaudited) Three Months Ended
March 31 --------------------- 2006 2005 -------- ------- Revenues
$ 54 $ 57 Operating expenses: Research and development 7,174 4,287
Selling, general and administrative 3,800 1,293 -------- -------
Total operating expenses 10,974 5,580 -------- ------- Operating
loss (10,920) (5,523) Interest income 312 64 Interest expense
(2,819) (305) -------- ------- Net loss $(13,427) $(5,764) ========
======= Basic and diluted net loss per share $ (0.17) $ (0.13)
======== ======= Shares used in computing basic and diluted net
loss per share 79,987 44,986 ======== ======= INSMED INCORPORATED
Consolidated Statements of Cash Flows (in thousands - unaudited)
Three Months Ended March 31 2006 2005 -------- ------- Operating
activities Net loss $(13,427) $(5,764) Adjustments to reconcile net
loss to net cash used in operating activities: Depreciation and
amortization 2,726 226 Stock based compensation expense 270 - Stock
options issued for services 20 - Changes in operating assets and
liabilities: Other assets 50 74 Accounts payable 1,275 (1,080)
Accrued project costs (1,986) (125) Payroll liabilities (648) 224
Restructuring reserve (82) (78) Asset retirement obligation 148 148
Interest payable (24) 80 -------- ------- Net cash used in
operating activities (11,678) (6,295) -------- ------- Financing
activities Proceeds from issuance of convertible debt with
detachable stock warrants - 35,000 Proceeds from issuance of common
stock Public offering - issuance of 23 million shares 43,240 -
Issuance costs (316) - Warrants converted into shares 8,810 - Other
28 87 -------- ------- Total proceeds from issuance of common stock
51,762 87 Costs incurred in conjunction with issuance of debt -
(2,428) Cash restricted to restricted letters of credit 288 185
-------- ------- Net cash provided by financing activities 52,050
32,844 -------- ------- Increase in cash and cash equivalents
40,372 26,549 Cash and cash equivalents at beginning of period
18,835 9,222 -------- ------- Cash and cash equivalents at end of
period $ 59,207 $35,771 ======== ======= Supplemental information
Cash paid for interest $ 83 $ - *T
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024